GNLX · GENELUX Corp
$2.87
+0.05 (+1.77%)
At close · Jul 17
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$128.69M
Shares
44.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$8000
0%
FY2025
Net Income
-$32.15M
-7.6%
FY2025
Operating Margin
-415175%
-18975pp
FY2025
Diluted EPS
-$0.86
+9.5%
FY2025
Operating Cash Flow
-$25.27M
-19%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $8000 | $8000 | $170K | $11.07M | |
| $20.93M | $19.85M | $19M | $12.77M | $9.08M | |
| $13.65M | $13.37M | $12.71M | $11.57M | $5M | |
| $34.58M | $33.22M | $31.7M | $24.34M | $14.08M | |
| -$34.57M | -$33.21M | -$31.7M | -$24.17M | -$3.01M | |
| — | -415175% | -396200% | -14214.71% | -27.22% | |
| — | — | — | $173K | — | |
| $700K | $711K | $700K | $182K | — | |
| $988K | $1.07M | $1.83M | -$4.13M | -$1.09M | |
| — | — | — | — | $1.1M | |
| -$33.58M | -$32.15M | -$29.87M | -$28.3M | -$5.21M | |
| — | -401812.5% | -373362.5% | -16645.29% | -47.05% | |
| -$33.62M | -$32.2M | -$29.82M | -$28.29M | -$5.21M | |
| USD/shares | — | -$0.86 | -$0.95 | -$1.16 | -$0.57 |
| USD/shares | — | -$0.86 | -$0.95 | -$1.16 | -$0.57 |
| shares | — | 37.18M | 31.45M | 31.45M | 9.12M |
| shares | — | 37.18M | 31.45M | 24.43M | 9.12M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.04×
P/E (TTM)
—
Biotechnology median 7.35×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating and Reportable Segments | $8,000 | $8,000 | $170,000 |